Ontology highlight
ABSTRACT:
SUBMITTER: Mauri G
PROVIDER: S-EPMC7795863 | biostudies-literature | 2021 Jan
REPOSITORIES: biostudies-literature
Mauri Gianluca G Bonazzina Erica E Amatu Alessio A Tosi Federica F Bencardino Katia K Gori Viviana V Massihnia Daniela D Cipani Tiziana T Spina Francesco F Ghezzi Silvia S Siena Salvatore S Sartore-Bianchi Andrea A
Cancers 20210104 1
The <i>BRAF<sup>V600E</sup></i> mutation is found in 8-10% of metastatic colorectal cancer (mCRC) patients and it is recognized as a poor prognostic factor with a median overall survival inferior to 20 months. At present, besides immune checkpoint inhibitors (CPIs) for those tumors with concomitant MSI-H status, recommended treatment options include cytotoxic chemotherapy + anti-VEGF in the first line setting, and a combination of EGFR and a BRAF inhibitor (cetuximab plus encorafenib) in second ...[more]